Verve Therapeutics’ (VERV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV) in a research note published on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock.

A number of other equities research analysts also recently issued reports on the company. Royal Bank of Canada lowered their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Verve Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.50.

Verve Therapeutics Stock Up 1.0 %

Shares of NASDAQ VERV opened at $5.84 on Tuesday. The business has a 50-day simple moving average of $6.98 and a two-hundred day simple moving average of $6.09. Verve Therapeutics has a 52 week low of $4.31 and a 52 week high of $13.63. The company has a market cap of $518.57 million, a P/E ratio of -2.37 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Equities research analysts anticipate that Verve Therapeutics will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Verve Therapeutics by 189.7% during the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after purchasing an additional 3,964 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after buying an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Verve Therapeutics in the 4th quarter worth approximately $50,000. Erste Asset Management GmbH purchased a new stake in Verve Therapeutics in the third quarter worth approximately $56,000. Finally, Impact Partnership Wealth LLC bought a new position in Verve Therapeutics during the fourth quarter valued at approximately $70,000. Institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.